The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Temozolomide As Initial Treatment for Adults With Low-Grade Oligodendrogliomas or Oligoastrocytomas and Correlation With Chromosome 1p Deletions
Open accessAbstract
Purpose: To determine the response rate of low-grade oligodendroglial tumors (LGOT) to temozolomide (TMZ) as initial treatment and to evaluate the predictive value of chromosome 1p deletion on the radiologic response. Patients and Methods: Adult patients with pathologically proven LGOT with progressive disease on magnetic resonance imaging (MRI) were eligible for the study. TMZ was administered at the starting dose of 200 mg/m 2/d for 5 days, repeated every 28 days. Response was evaluated clinically and by central review of MRIs. Chromosome 1p and 19q deletions were detected by the loss of heterozygosity technique. Results: Sixty consecutive patients were included in the study. At the time of analysis, the median number of TMZ cycles delivered was 11. Clinically, 51% of patients improved, particularly those with uncontrolled epilepsy. The objective radiologic response rate was 31% (17% partial response and 14% minor response), whereas 61% of patients had stable disease and 8% experienced disease progression. The median time to maximum tumor response was 12 months (range, 5 to 20 months). Myelosuppression was the most frequent side effect, with grade 3 to 4 toxicity in 8% of patients. Loss of chromosome 1p was associated with objective tumor response (P < .004). Conclusion: TMZ is well tolerated and provides a substantial rate of response in LGOT. Chromosome 1p loss is correlated with radiographic response and could be a helpful marker for guiding therapeutic decision making in LGOT.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cairncross, J. G., Ueki, K., Zlatescu, M. C., Lisle, D. K., Finkelstein, D. M., Hammond, R. R., Silver, J. S., Stark, P. C., Macdonald, D. R., Ino, Y., et al. (1998) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/90.19.1473 · Cited by 1,610
Primary brain tumours in adults
Ricard, D., Idbaih, A., Ducray, F., Lahutte, M., Hoang-Xuan, K., & Delattre, J.-Y. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61346-9 · Cited by 1,201
Self-citationSmith, J. S., Perry, A., Borell, T. J., Lee, H. K., O’Fallon, J., Hosek, S. M., Kimmel, D., Yates, A., Burger, P. C., Scheithauer, B. W., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.3.636 · Cited by 804
Primary brain tumours in adults
Behin, A., Hoang-Xuan, K., Carpentier, A. F., & Delattre, J.-Y. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12328-8 · Cited by 754
Self-citationShaw, E., Arusell, R., Scheithauer, B., O’Fallon, J., O’Neill, B., Dinapoli, R., Nelson, D., Earle, J., Jones, C., Cascino, T., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.09.126 · Cited by 730
Karim, A. B. M. F., Maat, B., Hatlevoll, R., Menten, J., Rutten, E. H. J. M., Thomas, D. G. T., Mascarenhas, F., Horiot, J. C., Parvinen, L. M., van Reijn, M., et al. (1996) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(96)00352-5 · Cited by 694
REIFENBERGER, J., Reifenberger, G., Liu, L., James, C. D., Wechsler, W., & Collins, V. P. (1994) · PubMed Central · Cited by 601
Khanna, C., Anderson, P. M., Hasz, D. E., Katsanis, E., Neville, M., & Klausner, J. S. (1997) · Cancer · doi:10.1002/(sici)1097-0142(19970401)79:7 · Cited by 561
Continuous growth of mean tumor diameter in a subset of grade II gliomas
Mandonnet, E., Delattre, J., Tanguy, M., Swanson, K. R., Carpentier, A. F., Duffau, H., Cornu, P., Van Effenterre, R., Alvord, E. C., & Capelle, L. (2003) · Annals of Neurology · doi:10.1002/ana.10528 · Cited by 493
Self-citationKeles, G. E., Lamborn, K. R., & Berger, M. S. (2001) · Journal of Neurosurgery · doi:10.3171/jns.2001.95.5.0735 · Cited by 488
Cairncross, G., Macdonald, D., Ludwin, S., Lee, D., Cascino, T., Buckner, J., Fulton, D., Dropcho, E., Stewart, D., & Schold, C. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.10.2013 · Cited by 442
Ino, Y., Betensky, R. A., Ƶlatescu, M. C., Sasaki, H., Macdonald, D. R., Stemmer-Rachamimov, A. O., Ramsay, D. A., Cairncross, J. G., & Louis, D. N. (2001) · PubMed · Cited by 432
Karim, A. B. M. F., Afra, D., Cornu, P., Bleehan, N., Schraub, S., De Witte, O., Darcel, F., Stenning, S., Pierart, M., & Van Glabbeke, M. (2002) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(01)02692-x · Cited by 389
Self-citationLong-term outcome of low-grade oligodendroglioma and mixed glioma
Olson, J. D., Riedel, E., & DeAngelis, L. M. (2000) · Neurology · doi:10.1212/wnl.54.7.1442 · Cited by 340
van den Bent, M. J., Taphoorn, M. J. B., Brandes, A. A., Menten, J., Stupp, R., Frenay, M., Chinot, O., Kros, J. M., van der Rijt, C. C. D., Vecht, C. J., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.12.015 · Cited by 297
Pace, A., Vidiri, A., Galiè, E., Carosi, M., Telera, S., Cianciulli, A. M., Canalini, P., Giannarelli, D., Jandolo, B., & Carapella, C. M. (2003) · Annals of Oncology · doi:10.1093/annonc/mdg502 · Cited by 263
Phase II study of primary temozolomide chemotherapy in patients with WHO grade II gliomas
Brada, M., Viviers, L., Abson, C., Hines, F., Britton, J., Ashley, S., Sardell, S., Traish, D., Gonsalves, A., Wilkins, P., et al. (2003) · Annals of Oncology · doi:10.1093/annonc/mdg371 · Cited by 261
Phase II Trial of Temozolomide in Patients With Progressive Low-Grade Glioma
Quinn, J. A., Reardon, D. A., Friedman, A. H., Rich, J. N., Sampson, J. H., Provenzale, J. M., McLendon, R. E., Gururangan, S., Bigner, D. D., Herndon, J. E., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.01.009 · Cited by 258
Buckner, J. C., Gesme, D., O’Fallon, J. R., Hammack, J. E., Stafford, S., Brown, P. D., Hawkins, R., Scheithauer, B. W., Erickson, B. J., Levitt, R., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.06.023 · Cited by 249
Daumas-Duport, C., Varlet, P., Tucker, M.-L., Beuvon, F., Cervera, P., & Chodkiewicz, J.-P. (1997) · Journal of Neuro-Oncology · doi:10.1023/a:1005707203596 · Cited by 230
Oligodendrogliomas: Reproducibility and prognostic value of histologic diagnosis and grading
Giannini, C., Scheithauer, B. W., Weaver, A. L., Burger, P. C., Kros, J. M., Mork, S., Graeber, M. B., Bauserman, S., Buckner, J. C., Burton, J., et al. (2001) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/60.3.248 · Cited by 219
Low-grade oligodendroglioma responds to chemotherapy
Mason, W. P., Krol, G. S., & DeAngelis, L. M. (1996) · Neurology · doi:10.1212/wnl.46.1.203 · Cited by 218
van den Bent, M. J., Kros, J. M., Heimans, J. J., Pronk, L. C., van Groeningen, C. J., Krouwer, H. G. J., Taphoorn, M. J. B., Zonnenberg, B. A., Tijssen, C. C., Twijnstra, A., et al. (1998) · Neurology · doi:10.1212/wnl.51.4.1140 · Cited by 206
Chromosomal anomalies in oligodendroglial tumors are correlated with clinical features
van den Bent, M. J., Looijenga, L. H. J., Langenberg, K., Dinjens, W., Graveland, W., Uytdewilligen, L., Sillevis Smitt, P. A., Jenkins, R. B., & Kros, J. M. (2003) · Cancer · doi:10.1002/cncr.11187 · Cited by 196
Chinot, O.-L., Honore, S., Dufour, H., Barrie, M., Figarella-Branger, D., Muracciole, X., Braguer, D., Martin, P.-M., & Grisoli, F. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.9.2449 · Cited by 179
Sasaki, H., Ƶlatescu, M. C., Betensky, R. A., Johnk, L., Cutone, A. N., Cairncross, J. G., & Louis, D. N. (2002) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/61.1.58 · Cited by 142
Molecular heterogeneity of oligodendrogliomas suggests alternative pathways in tumor progression
Hoang‐Xuan, K., He, J., Huguet, S., et al. (2001) · Neurology · doi:10.1212/wnl.57.7.1278 · Cited by 124
Self-citationNeoadjuvant procarbazine, CCNU, and vincristine for anaplastic and aggressive oligodendroglioma
Paleologos, N. A., Macdonald, D. R., Vick, N. A., & Cairncross, J. G. (1999) · Neurology · doi:10.1212/wnl.53.5.1141 · Cited by 79
Impact of Chromosome 1p Status in Response of Oligodendroglioma to Temozolomide: Preliminary Results
Chahlavi, A., Kanner, A. A., Peereboom, D. M., Staugaitis, S. M., Elson, P. J., & Barnett, G. H. (2003) · Journal of Neuro-Oncology · doi:10.1023/a:1022580610598 · Cited by 68
fMRI Occipital Activation by Tactile Stimulation in a Blind Man
Sadato, N., & Hallett, M. (1999) · Neurology · doi:10.1212/wnl.52.2.423 · Cited by 22
Cited by
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,609
Primary brain tumours in adults
Ricard, D., Idbaih, A., Ducray, F., Lahutte, M., Hoang-Xuan, K., & Delattre, J.-Y. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61346-9 · Cited by 1,201
Self-citationCairncross, G., Wang, M., Shaw, E., Jenkins, R., Brachman, D., Buckner, J., Fink, K., Souhami, L., Laperriere, N., Curran, W., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.2674 · Cited by 1,156
van den Bent, M., Afra, D., de Witte, O., Hassel, M. B., Schraub, S., Hoang-Xuan, K., Malmström, P.-O., Collette, L., Piérart, M., Mirimanoff, R., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67070-5 · Cited by 1,035
Self-citationJenkins, R. B., Blair, H., Ballman, K. V., Giannini, C., Arusell, R. M., Law, M., Flynn, H., Passe, S., Felten, S., Brown, P. D., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1796 · Cited by 763
Metadata
- Authors
- Hoang-Xuan, K., Capelle, L., Kujas, M., Taillibert, S., Duffau, H., Lejeune, J., Polivka, M., Crinière, E., Marie, Y., Mokhtari, K., Carpentier, A. F., Laigle, F., Simon, J. M., Cornu, P., Broët, P., Sanson, M., & Delattre, J. Y.
- Venue
- Journal of Clinical Oncology
- Published
- 2004-08-01
- Volume
- 22
- Issue
- 15
- Pages
- 3133-3138
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2130948002
- Cited by
- 356
- References
- 30
- FWCI
- 16.96
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.